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Background: Gender differences may occur in many chronic diseases. We have examined the
influence of gender in chronic obstructive pulmonary disease (COPD) on long-term responses
to tiotropium.
Methods: Subgroup analysis of data from the Understanding the Potential Long-term Impact of
Tiotropium (UPLIFT) trial (4-year, randomized, double-blind, placebo-controlled trial of tio-
tropium in patients with COPD).
Results: Of 5992 patients, 75% were men and 25% women. Mean age was 65 and 63 years,
respectively. Baseline post-bronchodilator forced expiratory volume in 1 s (FEV1)Z 47%
predicted(men) and 49% predicted(women). St George’s Respiratory Questionnaire (SGRQ)
total score was 44.9 and 48.7 units, respectively. At 48 months, improvement in trough
FEV1 over control was 92 mL(men) and 77 mL(women) (p< 0.001 for both), with no differ-
ences in the rate of decline (trial primary endpoint). Hazard ratio (HR) (95% confidence
interval [CI]) for first exacerbation (tiotropium/placebo) was 0.87(0.81, 0.93)(men) and
0.83(0.74, 0.94)(women). Number of exacerbations (per patient-year) was reduced with
tiotropium in men (from 0.82 to 0.71) and women (from 0.92 to 0.77) (p< 0.005 for both).
HR (95% CI) for a hospitalized exacerbation was 0.89(0.79, 0.99) and 0.77(0.62, 0.94),
respectively. HR (95% CI) for mortality during treatment was 0.85(0.72, 0.99)(men) and
0.85(0.62, 1.18)(women). Improvements in SGRQ total score (tiotropiumecontrol) at 1, 2,
3 and 4 years were: 2.8, 2.3, 3.6, 2.4(men) and 2.7, 2.6, 2.6, 2.1(women)
(p< 0.05 for all).825 3163; fax: þ1 310 206 5088.
ucla.edu (D. Tashkin).
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Chronic obstructive pulmonary disease (COPD) is becoming
increasingly more prevalent in women in many societies.
Gender differences and similarities in COPD have been
reported with regard to diagnosis and prevalence, although
men continue to have higher prevalence rates and women
may have a steeper rise in mortality due to COPD.1e5
Whether gender per se influences susceptibility to the
development of COPD remains a matter of debate.6e10
A recent systematic review of population-based cohort
studies of current smokers showed that females had
a significantly faster annual decline in percent predicted
forced expiratory volume in 1 s (FEV1) with increasing age
than males.11 In the Lung Health Study, women with mild to
moderate airflow limitation demonstrated greater airway
hyper-responsiveness than men for the same degree of
airflow obstruction12; the potential importance of which is
suggested by the observation that airway hyper-
responsiveness in COPD is a significant predictor of the
subsequent rate of decline in lung function.13 That the
pathophysiology of airflow limitation may differ between
men and women is also suggested by the finding from a lung
cancer screening trial using computed tomography (CT)
scans in current and ex-smokers that, for the same degree of
airflow limitation, at all stages of COPD severity women have
less CT emphysema than men.14 Moreover, among patients
with emphysema participating in the National Emphysema
Treatment Trial, women had less severe emphysema for the
same percent predicted FEV1 than men, but, in a subset of
histological sections, women had thicker small airway walls
relative to luminal size,15 suggesting a gender disparity in the
mix between airway and lung parenchymal pathology.
Gender differences have also been noted in the response
of COPD subjects to various interventions. In intervention
studies centered largely on smoking cessation, women
exhibited lower sustained smoking abstinence rates than
men,16,17 even after administration of nicotine replacement
therapy.18 Gender differences have also been reported in the
lung function response to smoking cessation and smoking
relapse among participants in the Lung Health Study, women
exhibiting greater improvements in FEV1 than men a year
after successful quitting but reciprocally greater declines in
FEV1 after relapse.
17 Differences have also been noted in the
response of women with COPD to inhaled corticosteroid
therapy compared to men, the former showing greater
absolute improvements in FEV1 in the first 6e12months after
initiation of inhaled corticosteroids.19 Although women
appear to show less short-term reversibility than men in
response to short-acting inhaled bronchodilators, this
difference depends on how reversibility is defined.20
It is also not clear whether women might differ from
men in their long-term responses to pharmacotherapy forCOPD. In a sensitivity analysis of the comparative responses
of male and female COPD subjects to treatment for 1-year
with the combination of salmeterol and fluticasone versus
placebo, Vestbo et al. reported numerically larger FEV1
responses in women than men, as well as slight gender
differences in the reduction in COPD exacerbations and
improvement in health-related quality of life (HRGL) with
the long-acting b-agonist and inhaled corticosteroid
combination, but none of these differences achieved
statistical significance.21 Moreover, no significant gender
differences were noted for the effect of salmeterol, fluti-
casone or the salmeterol/fluticasone combination on FEV1
decline in the Towards a Revolution in COPD Health
(TORCH) trial.22 The present study analyses data from the
Understanding the Potential Long-term Impact of Tio-
tropium (UPLIFT) trial22 to address the question whether
or not gender differences occur in a broad range of thera-
peutic responses to long-term (4-year) therapy with the
long-acting anti-cholinergic bronchodilator tiotropium.
Methods
Study design
The design and main results of the UPLIFT trial have
previously been published in detail.23,24 To summarize,
UPLIFT was a randomized, double-blind, parallel-group,
placebo-controlled trial of 4 years’ duration in which all
patients were permitted use of all respiratory medications
throughout the trial, other than inhaled anti-cholinergics to
be included, patients were required to have a diagnosis of
COPD, post-bronchodilator FEV1< 70% predicted normal,
post-bronchodilator FEV1 to forced vital capacity (FVC)
ratio 0.70, be 40 years of age and have smoked 10
pack-years. Patients were excluded if they had an exacer-
bation of respiratory infection within 4 weeks prior to
screening, pulmonary resection, any history of asthma,
12 h/day use of supplemental oxygen or a significant
disease that would interfere with their participation or the
interpretation of the trial outcomes. Ethics committee
approval was granted for all participating centers and
written informed consent was obtained in all patients.
The annual rates of decline in both pre- and post-
bronchodilator FEV1 from 30 days post-randomization to
the end of the protocol defined treatment period were
designated as co-primary endpoints. Pre-specified key
secondary endpoints were time to first exacerbation and
exacerbation leading to hospitalization. Other secondary
endpoints included pre- and post-bronchodilator FEV1, FVC
and slow vital capacity (SVC) measured at clinic visits,
number of COPD exacerbations and hospitalizations due to
exacerbations, HRQL (assessed with the St George’s Respi-
ratory Questionnaire [SGRQ]) and mortality.25
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Clinic visits were scheduled at baseline, 30 days’ post-
randomization, every 3 months following randomization and
then 30 days after completion of the study. Spirometry was
performed according to American Thoracic Society criteria
both before and following sequentially administered short-
acting bronchodilators (ipratropium bromide four actua-
tions, salbutamol four actuations 60 min later and spirometry
performed 30 min after salbutamol).26 Following randomiza-
tion, studymedicationwas administered immediately prior to
short-acting bronchodilators. Spirometry was performed at
baseline, 30 days following randomization, at 6-monthly
intervals post-randomization and 30 days following comple-
tion of study medication. The SGRQ was administered at
baseline and every 6months post-randomization. Information
regarding exacerbations, medications and adverse events
were collected at all clinic visits. For patients who dis-
continued studymedication prematurely, a follow-up visit for
spirometry was requested 30 days following the last dose of
study medication. Vital status information was sought for all
prematurely discontinued patients.27Statistical analysis
The annualized change in FEV1, FVC and SVC (expressed
both as absolute ml change and as percent of predicted
normal to adjust for gender differences in the predicted
values) was analyzed with random co-efficient regression in
which the spirometric variable changed linearly after 30
days for each patient, intercepts and slopes were random
and the treatment effect was fixed. The identical analysis
was used for the change in SGRQ from 6 months until
completion of the study. All randomized patients receiving
study medication having at least three post-randomization
spirometry measurements (at least two for the SGRQ)
were used in the analyses of decline. SGRQ values from
Turkey were not included due to a translation error.
Spirometry and SGRQ values at clinic visits were modeled
using mixed model repeated measures analysis of variance
with random subject effects. The same criterion as listed
above was used (i.e., three post-randomization measure-
ments of spirometry, two for SGRQ). Time to first exacerba-
tion, first hospitalized exacerbation and mortality were
analyzed by Cox regression. Poisson regression with correc-
tion for over dispersion was used to calculate and compare
the number of events and event days. Analyses were per-
formed with SAS software, version 8.2 (SAS Institute, Cary,
North Carolina, USA). p-values reported are two-sided
without correction for multiple testing. Further details of
the statistical analysis plan have been published.23
Adverse events were recorded according to the Medical
Dictionary for Regulatory Activities (MeDRA; version 11.0).
Individual events are referred to as preferred terms, which
are categorized according to system organ classes. Inci-
dence rates were determined from the number of patients
with an event divided by the cumulative exposure time at
risk within a treatment group and expressed per 100
patient-years. Incidence rate ratios (tiotropium/control)
along with 95% confidence intervals (CI) were calculated as
a measure of relative risk for an event.For the above analyses, the models used provided
gender-specific results. To assess interaction, tests exam-
ined whether the addition of an interaction term for gender
by treatment provided a significant improvement over
a model that included main effects for gender and treat-
ment, but no interaction term. This allowed us to deter-
mine if there were differential treatment effects by
gender.
Results
Patient demographics
Patients were recruited from the practices of mostly
pulmonary specialists from 37 countries in different regions
of the world (Americas; Europe/Republic of South Africa
[RSA]; Asia/Pacific). The percentages of women random-
ized from the different regions were 33.3% (Americas),
23.2% (Europe/RSA) and 5.2% (Asia/Pacific). Of the 5992
randomized COPD patients receiving study medication,
there were 2251 men and 735 women assigned to the tio-
tropium group, and 2222 men and 784 women assigned to
the placebo arm. Baseline characteristics, including base-
line respiratory medications, are shown in Table 1 for men
and women separately by treatment assignment. For each
gender, baseline features were similar between the two
treatment arms. Within each treatment category, age and
body mass index (BMI) were similar for men and women.
Duration of diagnosed COPD and mean values for COPD
severity, as defined by the percent predicted FEV1, were
also comparable, although the absolute FEV1 was lower for
women, as expected, and slightly more women than men
were categorized as having moderate disease severity
(Global Initiative for Chronic Obstructive Lung Disease
Guidelines [GOLD] stage II). Moreover, despite the simi-
larity in percent predicted FEV1, women reported fewer
pack-years of cumulative smoking over their lifetime.
According to the SGRQ total score, women reported lower
health-related quality of life by approximately three units.
A higher proportion of men (55e56%) than women (42e43%)
exhibited a significant bronchodilator response defined as
a 12%þ 200 ml increase in FEV1 post-bronchodilator;
however, the proportions of those with a significant bron-
chodilator response within each gender category were
similar between the two treatment arms. The proportions
of men and women reporting concomitant maintenance
respiratory medication at baseline were comparable.
A higher proportion of patients discontinued the trial
prematurely in the placebo group in men (43.4% placebo
versus 36.1% tiotropium) and in women (50.3% placebo
versus 38.9% tiotropium), with proportionally more women
than men discontinuing trial participation overall (44.8%
versus 39.7%, respectively) (Fig. 1). The most common
reason for discontinuing participation in the trial was an
adverse event in both groups.
Lung function
Pre- and post-bronchodilator values for FEV1 at each time
point over the course of the study are shown for each
treatment group for men and women separately in Fig. 2a.
Table 1 Demographics (a) and respiratory medications used prior to randomization (b) according to gender in the UPLIFT
trial in the tiotropium and control groups.
Men Women
Tiotropium
(nZ 2251)
Control
(nZ 2222)
Tiotropium
(nZ 735)
Control
(nZ 784)
(a) Demographics
Age (years) 65 8 65 8 63 9 62 9
BMI 26 5 26 5 26 6 25 6
Smoking status
Current (%) 28 26 34 40
History (pack-years) 51 29 51 29 42 23 40 21
Duration of COPD (years) 10 8 10 7 9 7 10 8
GOLD stage [N (%)]
II 997 (44) 979 (44) 387 (53) 376 (48)
III 1021 (45) 991 (45) 283 (39) 340 (43)
IV 194 (9) 214 (10) 56 (8) 57 (7)
SGRQ total score (units) 45 17 45 17 48 16 49 17
FEV1 (l)
Pre-bronchodilator 1.17 0.40 1.16 0.40 0.89 0.31 0.89 0.31
Post-bronchodilator 1.41 0.44 1.40 0.44 1.08 0.34 1.07 0.33
FEV1 (% predicted)
Pre-bronchodilator 39 12 39 12 40 12 40 12
Post-bronchodilator 47 13 47 13 49 13 49 13
Patients with 12%þ 200 mL increase in
FEV1 post-bronchodilator (%)
56 55 42 43
FVC (l)
Pre-bronchodilator 2.83 0.77 2.84 0.81 2.02 0.58 2.02 0.55
Post-bronchodilator 3.32 0.80 3.34 0.86 2.38 0.63 2.39 0.61
FVC (% predicted)
Pre-bronchodilator 74 18 74 18 77 18 77 17
Post-bronchodilator 87 18 87 19 91 20 91 18
(b) Concomitant respiratory medications [N (%)]
Any pulmonary medication 2107 (94) 2060 (93) 681 (93) 740 (94)
Anti-cholinergics (long-acting) 46 (2) 40 (2) 14 (2) 9 (1)
Anti-cholinergics (short-acting)a 1018 (45) 975 (44) 324 (44) 350 (45)
b-agonists (long-acting)a 1349 (60) 1316 (59) 447 (61) 492 (63)
b-agonists (short-acting)a 1518 (67) 1472 (66) 526 (72) 575 (73)
Leukotriene receptor antagonists 54 (2) 51 (2) 44 (6) 43 (5)
Mucolytics 176 (8) 170 (8) 46 (6) 38 (5)
Supplemental oxygen 35 (2) 41 (2) 33 (4) 16 (2)
Steroids (inhaled)a 1366 (61) 1369 (62) 474 (64) 491 (63)
Steroids (other) 193 (9) 181 (8) 58 (8) 70 (9)
Theophyllines 676 (30) 668 (30) 174 (24) 190 (24)
Values displayed as mean SD unless otherwise stated.
BMI; body mass index; COPD, chronic pulmonary obstructive disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease
Guidelines; SGRQ, George’s Respiratory Questionnaire; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
a Alone or in combination in a fixed-dose product.
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FEV1, similar significant improvements with tiotropium
relative to control were observed in both groups, with the
absolute improvements in FEV1 being slightly less in women
but the percent predicted improvements are fairly
comparable in men and women. Similar findings were
observed for changes in FVC (Fig. 2b). In each treatmentgroup, rates of decline in both pre- and post-bronchodilator
FEV1 and FVC were slightly lower for women than for men in
absolute terms, but similar when expressed as the yearly
decline in the percent of predicted (Table 2). The
tiotropium-placebo differences in the rates of decline were
comparable for men and women. There was no evidence of
an interaction with treatment by gender. The rate of
1 did not receive 
tiotropium
2987 assigned to
tiotropium
3006 assigned to placebo 
(control)
2251 men received 
tiotropium
735 women received 
tiotropium
2222 men received 
placebo
784 women received 
placebo
8020 patients assessed 
for eligibility
5992 patients randomised
2027 withdrew/did not 
meet entry criteria
1438 completed the 
study
449 completed the 
study
1258 completed the 
study
390 completed the 
study
813 discontinued
483 had an adverse 
event
175 worsening COPD
34 protocol non-
compliance
209 consent 
withdrawn
52 lost to follow up
286 discontinued
144 had an adverse 
event
63 worsening COPD
14 protocol non-
compliance
91 consent withdrawn
91 lost to follow up
964 discontinued
550 had an adverse 
event
252 worsening COPD
52 protocol non-
compliance
267 consent 
withdrawn
59 lost to follow up
394 discontinued
196 had an adverse 
event
116 worsening COPD
23 protocol non-
compliance
136 consent 
withdrawn
17 lost to follow up
Figure 1 Study population enrolment and outcomes.
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(range: 0.6e0.8%/year) and post-bronchodilator FEV1
(range: 0.9e1.2%/year) was similar in men and women.
Since the proportion of men exhibiting significant bron-
chodilator responsiveness at baseline (12% plus >200 ml
increase in FEV1) was higher in men than women, we per-
formed the following additional analyses: rate of decline in
FEV1 and FVC for those meeting the reversibility criterion
and rate of decline in FEV1 and FVC for those not meeting
it. For these analyses, pre-bronchodilator and post-
bronchodilator rates of decline were analyzed within the
gender subgroups. While some differences in the annual
rates of decline in FEV1 were noted between reversibility
categories, no significant gender differences in rates of
decline were noted between treatment groups for either
reversible or non-reversible patients; however, it is
acknowledged that a bias is introduced by having the
200 ml criteria when comparing men and women due to the
smaller lungs of women (i.e., 200 ml represents a higher
fraction of the FEV1 for women).
Exacerbations
In each treatment arm, a similar proportion of men
(approximately 67%) and women (approximately 68%) had
at least one exacerbation during the course of the study.
Both men and women showed a significant benefit of tio-
tropium with respect to a reduction in the risk for an
exacerbation (hazard ratio [HR] [95% CI]Z 0.87
[0.81e0.93] and 0.83 [0.74e0.94], respectively) and an
exacerbation leading to a hospitalization (HR [95% CI]
Z 0.89 [0.79e0.99] and 0.77 [0.62e0.94], respectively)(Table 3). The rate of exacerbations was lower in the tio-
tropium group compared to the placebo group. The rates of
hospitalization were low and reduced with tiotropium for
women but similar for men (Table 3), with the interaction p
value being 0.06.
Health-related quality of life
Both men and women had statistically significant improve-
ments in SGRQ total scores during the trial. While women
had slightly worse (higher) total SGRQ scores than men at
baseline, in general they showed similar tiotropium-related
improvements in overall HRQL (Fig. 3).
Mortality
Mortality was assessed using three approaches: (a) during
the actual treatment period (first dose to last doseþ 30
days), (b) during the protocol defined treatment period
(Day 1440) including collection of vital status information
from prematurely discontinued patients, and (c) at the
conclusion of a 30-day period after the protocol defined
treatment period (Day 1470). Vital status collection was
complete for 96% of patients at Day 1440 and only 75% at
the end of the subsequent 30-day washout. In each treat-
ment arm, the all-cause mortality rate was greater for men
than for women for all three analyses (Table 4). The HRs
(tiotropium/placebo), other than for women including the
30-day washout period, were less than 1, indicating
a benefit of tiotropium in reducing mortality while
receiving treatment with tiotropium; however, the CIs
exclude 1 only for men both during treatment and including
Figure 2 Pre- and post-bronchodilator FEV1 (a) and FVC (b) by gender in the tiotropium and control groups over 48 months.
The horizontal lines represent the mean baseline pre- and post-bronchodilator values. *p< 0.001.
1500 D. Tashkin et al.vital status up until the end of the protocol defined treat-
ment period. For lower respiratory mortality, all hazard
ratios are below 1 with CIs that include unity.
Adverse events
The most common adverse events were lower respiratory
tract disorders (i.e., exacerbations [65.2% men, 66.1%
women], pneumonia [14.8% men, 12.3% women] and dysp-
nea [12.6% men and 15.9% women]) followed by upper
respiratory tract disorders (i.e., nasopharyngitis [11.1%Table 2 Annualized rates of FEV1 and FVC (mean [SEM]) declin
Tiotropium Control
Mean yearly decline Mean y
n mL % pred n
FEV1 pre-bronchodilator
Men 1946 31 (1) 0.6 (0.1) 1815
Women 611 27 (3) 0.8 (0.1) 598
FEV1 post-bronchodilator
Men 1945 41 (1) 0.9 (0.1) 1812
Women 609 35 (3) 1.0 (0.1) 598
FVC pre-bronchodilator
Men 1946 43 (3) 0.6 (0.1) 1815
Women 611 40 (5) 0.7 (0.2) 598
FVC post-bronchodilator
Men 1945 64 (3) 1.1 (0.1) 1812
Women 609 52 (5) 1.1 (0.2) 598
*Tiotropium e control, all p-values 0.1.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; % pmen, 13.2% women], upper respiratory tract infection [9.6%
men, 10.5% women]). The risk for a lower or upper respi-
ratory tract disorder with respect to treatment assignment
appeared similar for men and women. For all cardiac
adverse events, tiotropium was not associated with an
increased risk in either men (rate ratio [95% CI] 0.86
[0.76e0.98]) or in women (1.01 [0.79e1.29]). As expected,
lower respiratory tract disorders were the most common
serious adverse events (Table 5). Serious adverse events
recorded in the cardiac and neoplastic systems overall were
more common in men than women; however, respiratorye according to gender in the tiotropium and control groups.
Difference
early decline TiotropiumeControl
mL % pred mL % pred
31 (2) 0.7 (0.1) 0 (2) 0.0 (0.1)
27 (3) 0.7 (0.1) 1 (4) 0.0 (0.1)
43 (2) 1.0 (0.1) 2 (2) 0.1 (0.1)
39 (3) 1.2 (0.1) 4 (4) 0.2 (0.1)
39 (3) 0.5 (0.1) 4 (4) 0.1 (0.1)
37 (6) 0.6 (0.2) 3 (8) 0.1 (0.2)
62 (3) 1.0 (0.1) 3 (4) 0.1 (0.1)
57 (6) 1.3 (0.2) 6 (8) 0.2 (0.2)
red, percent of predicted.
Table 3 Exacerbations and exacerbations leading to hospitalizations according to gender in the tiotropium and control groups.
Hazard ratio (95% CI) Number of events (per patient-year [SE]) Rate ratio (95%CI)
Tiotropium/Control Tiotropium Control Tiotropium/Control
Exacerbations
Men 0.87 (0.81e0.93) 0.71 (0.02) 0.82 (0.02) 0.87 (0.81e0.93)
Women 0.83 (0.74e0.94) 0.77 (0.03) 0.92 (0.04) 0.84 (0.74e0.94)
Hospitalized exacerbations
Men 0.89 (0.79e0.99) 0.16 (0.01) 0.16 (0.01) 1.01 (0.86e1.17)
Women 0.77 (0.62e0.94) 0.13 (0.01) 0.18 (0.02) 0.75 (0.57e0.98)
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lung cancer, appears at similar rates in men and women.Discussion
Previous studies have suggested that women with COPD
differ from men in their short-term responses to broncho-
constrictor and bronchodilator agents,12,13 as well as in
their longer-term responses to inhaled corticosteroid
therapy.19 Women also appeared to show greater
improvements in pre-bronchodilator FEV1 than men during
a 1-year trial with a long-acting b-agonist and inhaled
corticosteroid combination, but the differences were not
statistically significant21 and no significant gender-related
differences were noted in a subsequent placebo-
controlled 3-year trial of a long-acting b-agonist and
inhaled corticosteroid either alone or in combination.22
Since one-quarter, or 1519, of the participants in the
recently published 4-year, placebo-controlled trial of tio-
tropium involving 5992 patients with COPD (UPLIFT) were
women,22 UPLIFT provided a unique opportunity to
examine possible differences in the long-term physiological
and clinical responses of male and female subjects with
COPD to daily therapy with a long-acting anti-cholinergic
bronchodilator in a setting applicable to healthcare
professionals (i.e., allowance for concomitant maintenance
respiratory medication other than inhaled anti-cholinergics
during the trial).
Although some differences were noted in the baseline
characteristics of the male and female UPLIFT trial
participants, such features as age, BMI, duration of COPD,
COPD severity and concomitant respiratory medication
were reasonably well matched. The exceptions were that
slightly more women than men were current smokers
(albeit with a lower cumulative pack-year history of
smoking) and had GOLD stage II disease, average baseline
SGRQ scores were slightly higher (worse) in women and
a higher proportion of men exhibited significant broncho-
dilator responsiveness at baseline. However, all of these
features were well balanced between the two treatment
arms within each gender category. Consequently, it is
unlikely that maleefemale differences in some of the
baseline features had a significant confounding influence on
the analysis of possible gender differences in outcomes. On
the other hand, for the same percent predicted FEV1,
women have lower absolute values of FEV1 than men due to
maleefemale differences in airway caliber. It has been
argued that this difference in airway geometry is largelyresponsible for the greater bronchoconstrictor responses of
women to methacholine,12 presumably due to the expo-
nential relationship between the radius of the airway lumen
and airflow resistance (Poiseuille’s Law). However, since
women had lower mean absolute FEV1 values at baseline
then men in the UPLIFT trial, the latter mechanism could
not explain their slightly lower absolute pre-bronchodilator
FEV1 responses to the smooth muscle relaxant effect of
tiotropium compared to placebo over the course of the
trial.
Women exhibited rates of decline in FEV1 that were
slightly lower compared to men in both the tiotropium and
control arms of the trial, but, as in the case of the male
subjects, they showed very similar rates of decline between
the two treatments, indicating similar long-term physio-
logical responses to tiotropium between men and women
(Table 2). Similar results were obtained when separate
analyses were performed for those subjects meeting versus
not meeting American Thoracic Society/European Respira-
tory Society reversibility criteria at baseline. The lower
rates of change over time in absolute FEV1 in women may
be attributable to their lower mean absolute FEV1 for the
same gender-specific percent predicted FEV1, as suggested
by the similarity in the rates of change in percent predicted
FEV1 between men and women.
In UPLIFT, exacerbations were defined by the combi-
nation of more than one symptom, a minimum of 3 days
duration (to minimize the possibility the event represents
day-to-day variability) and an intervention by a healthcare
professional.23 Within each treatment arm, women had
a slightly higher incidence of exacerbations than men but
this did not impact the benefits of tiotropium observed in
both men and women. The reason for the numeric gender
difference in exacerbation rates is unclear, although the
difference may simply reflect variability in rates within the
trial. Alternative possible explanations include women’s
relatively smaller airway caliber, leading to a lower abso-
lute level of lung function for any given percent predicted
FEV1, a lower threshold among women for experiencing
dyspnea for any given acute decline in lung function or
a greater inclination to seek medical care for the same
decrement in lung function compared to men. Despite their
higher rate of exacerbations, women had a roughly similar
rate of exacerbation-related hospitalizations compared
with men, although the impact of tiotropium on the number
of these hospitalizations and on the time to the first
exacerbation-related hospitalization tended to be greater
in women. On the other hand, the data on exacerbation-
related hospitalizations are difficult to interpret because
Figure 3 St George’s Respiratory Questionnaire total score by gender in the tiotropium and control groups over 48 months.
*p< 0.01, ypZ 0.03.
1502 D. Tashkin et al.of the relatively small number of hospitalizations and the
potential impact of interventions following the first hospi-
talized exacerbation.
On average, women had worse health status (higher total
SGRQ scores) than men at baseline despite a similar severity
of disease as defined by FEV1 (percent predicted) and GOLD
stage. Similar gender differences in HRQL and symptoms of
COPD have been reported previously.28,29 Interestingly, total
SGRQ scores at the end of the trial tended to decline
(improve) frombaselinewith tiotropiummore inwomen than
in men. The reasons for this apparent disparity are not clear
but could be related to the fact that the baseline health
status was worse among women, thus leaving more room for
improvement in a therapeutic intervention trial. It is also
possible that women’s expectations for the benefits of
treatment might have been higher. On the other hand, the
favorable impact of tiotropium in improving these scores
compared to placebo overall 4 years of the trial was
comparable for both women and men.
The higher mortality rates in men than women were not
unexpected and were consistent with recently reported
findings that at a similar severity of COPD by body massTable 4 All-cause and lower respiratory mortality (hazard ratio
All-cause Mortality
Tiotropium
n (%)
Control
n (%)
Hazard ratio
(95% CI)
During treatment
Men 305 (13.5) 327 (14.7) 0.85 (0.72e0.
Women 69 (9.4) 75 (9.6) 0.85 (0.62e1.
Including vital status until the end of the protocol treatment per
Men 345 (15.3) 397 (17.9) 0.84 (0.73e0.
Women 85 (11.6) 94 (12.0) 0.96 (0.72e1.
Including vital status until the end of the washout period (day 14
Men 357 (15.9) 400 (18.0) 0.86 (0.75e1.
Women 89 (12.1) 95 (12.1) 1.00 (0.75e1.index, airflow obstruction, dyspnea, exercise capacity and
FEV1, women have a significantly lower mortality then
men.30 Tiotropium lowered the risk of all-cause mortality
for men but had less of an impact on mortality in women.
This difference could have been related to a greater
potential for a beneficial effect of active treatment on the
generally higher mortality risk in men.
In summary, while the minority of patients in the
UPLIFT trial were women, there were still over 1500
women. Men and women had generally similar demo-
graphics; however, proportionately more women (44.8%)
discontinued the trial prematurely than men (39.7%). Minor
gender differences were noted in the absolute level of
improvement in lung function and slight differences were
observed in exacerbation rates. Moreover, it appeared that
women had a higher degree of impairment in HRQL for
a similar reduction in FEV1. Nevertheless, men and women
showed comparable benefits with respect to sustained
improvements in FEV1 and FVC, in HRQL and in exacerba-
tions of COPD. The response for mortality appeared to be
similar during treatment with a trend towards a difference
when follow-up of prematurely discontinued patients was[95% CI]) by gender in the tiotropium and control groups.
Lower respiratory mortality
Tiotropium
n (%)
Control
n (%)
Hazard ratio
(95% CI)
99) 104 (4.6) 104 (4.7) 0.91 (0.69e1.19)
18) 27 (3.7) 36 (4.6) 0.69 (0.42e1.14)
iod (day 1440)
97) 117 (5.2) 129 (5.8) 0.88 (0.68e1.13)
29) 30 (4.1) 42 (5.4) 0.76 (0.48e1.22)
70)
00) 121 (5.4) 130 (5.9) 0.90 (0.70e1.15)
33) 32 (4.4) 43 (5.5) 0.79 (0.50e1.25)
Table 5 Most common serious adverse events (5% of population in either treatment group) according to system organ class
by gender in the tiotropium and control group.
System organ class Tiotropium Control Rate ratio (95% CI)
Tiotropium versus controln IRa n IRa
Respiratory system disorders (lower)
Men 710 11.61 751 13.67 0.85 (0.77e0.94)
Women 201 10.40 234 12.90 0.81 (0.67e0.97)
Respiratory system (other)
Men 124 1.74 117 1.79 0.97 (0.76e1.25)
Women 46 2.07 39 1.84 1.13 (0.73e1.72)
Gastrointestinal
Men 126 1.80 132 2.06 0.87 (0.68e1.11)
Women 45 2.06 35 1.67 1.23 (0.79e1.92)
Neoplasms
Men 154 2.20 138 2.15 1.02 (0.81e1.29)
Women 43 1.96 32 1.51 1.29 (0.82e2.04)
Cardiac
Men 265 3.85 290 4.65 0.83 (0.70, 0.98)
Women 57 2.62 60 2.89 0.91 (0.63, 1.30)
a IR, incidence rate (per 100 patient-years).
Effect of tiotropium in men and women with COPD 1503considered. The data from UPLIFT supports a similar
approach to maintenance inhaled anti-cholinergic therapy
in COPD in men and women.Acknowledgements
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